- VR Might Aid Stroke Recovery
- Weighted Vests Don’t Protect Bone Health In Dieting Seniors, Trial Says
- Studies Address Muscle Loss Caused By GLP-1 Drugs
- Blood Test Might Predict MS Relapse
- Cystic Fibrosis: Symptoms, Treatments, Causes & More
- Rival GLP-1 Weight-Loss Drug Emerges From China
- NIH to Fund $10M in Long-Term Health Studies After Ohio Train Disaster
- Trader Joe’s Recalls Garlic Cheese Curds Due to Listeria Risk
- FDA Recalls Chocolate Candies Over Milk Allergy Risk
- 100,000 Amazon Mattresses Recalled Over Fire Hazard
New Device Treats Superficial Varicose Veins

The VenaSeal closure system has been approved by the U.S. Food and Drug Administration to treat superficial varicose veins in the leg that appear close to the skin and cause an unsightly and sometimes painful condition.
The product, administered by a trained professional, is designed to seal the affected veins, preventing the pooling of blood in these vessels. It was clinically evaluated in a study of more than 200 participants, comparing it to another treatment called radio-frequency ablation.
“The trials showed the device to be safe and effective for vein closure for the treatment of symptomatic superficial varicose veins of the legs,” the FDA said Friday in a news release.
The VenaSeal system should not be used in people with a known sensitivity to the system’s adhesive, or in those with inflamed veins due to blood clots or infection. The most common side effects included vein inflammation and burning and tingling in the treatment area, the agency said.
The VenaSeal system is manufactured by Covidien LLC, in Morrisville, N.C.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.